DRKS00000716.

Methods	Randomised, active‐controlled, parallel‐group, simple blind Date of study: 3 June 2008 (starting date) Location: Germany
Participants	Inclusion criteria Aged 18 ‐ 65 years Clinical diagnosis of psoriasis for > 6 months Plaque‐type psoriasis (PASI > 10) BSA > 10% Exclusion criteria Contraindications for treatment with TNF‐alpha inhibitors and FAEs Women who are pregnant or who are breast‐feeding. Women of childbearing potential must follow a medically recognised form of contraception Currently receiving or have received within 4 weeks prior to first administration of study administration: systemic therapy for psoriasis; monoclonal antibody therapy for psoriasis; phototherapy TB anamnesis, infections (Hepatitis B, C, HIV) History of lymphoproliferative disorders, malignancies, demyelinating disease, severe heart failure History of substance abuse (drugs or alcohol) or any factor (e.g. serious psychiatric condition) which limits the patient’s ability to co‐operate with the study procedures Unco‐operative, known to miss appointments (according to patient’s records) and are unlikely to follow medical instructions or are not willing to attend regular visits
Interventions	Arm 1: Adalimumab (Humira): 80mg initial puis 40mg /2 weeks 24 weeks Arm 2: Etanercept (Enbrel): 50mg 2x/weeks s.c. 12 weeks puis 25mg 2x/weeks s.c. 12 weeks Arm 3: Fumaderm
Outcomes	Week 8: PASI DLQI Immunhistologie Week 24: PASI DLQI Immunhistologie
Notes	Starting date: 03 June 2008, Prof. Arnd Jacobi, Klinik für Dermatologie und Allergologie Philipps‐Universität Marburg Recruitment status on ICTRP search portal: complete: follow‐up complete We emailed Prof. Jacobi (5 January 2017) without response